Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Academic Article Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Hypothyroidism
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • Axitinib shows clinical activity in patients with cytokine-refractory metastatic renal-cell cancer. Although 28 patients had grade 3 or grade 4 treatment-related adverse events, these adverse events were generally manageable and controlled by dose modification or supportive care, or both. Further studies are needed to confirm these findings.

publication date

  • November 2007

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(07)70285-1

PubMed ID

  • 17959415

Additional Document Info

start page

  • 975

end page

  • 84

volume

  • 8

number

  • 11